Role of oral teriflunomide in the management of multiple sclerosis by Tanasescu R, Evangelou N, Constantinescu CS

Get full text

Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. by Evangelou, N, Littlewood, T, Anslow, P, Chapel, H

Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. by Evangelou, N, Jackson, M, Beeson, D, Palace, J

Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions by Evangelou, N, DeLuca, G, Owens, T, Esiri, M

Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. by Evangelou, N, DeLuca, G, Owens, T, Esiri, M

Spinal cord lesions play only a limited role in determining the degree of cord atrophy in multiple sclerosis by Evangelou, N, DeLuca, G, Owens, T, Esiri, M

Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. by Evangelou, N, Esiri, M, Smith, S, Palace, J, Matthews, P

The contribution of demyelination to axonal loss in multiple sclerosis by DeLuca, G, Williams, K, Evangelou, N, Ebers, G, Esiri, M

Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. by Evangelou, N, Konz, D, Esiri, M, Smith, S, Palace, J, Matthews, P

The contribution of demyelination to axonal loss in multiple sclerosis. by DeLuca, G, Williams, K, Evangelou, N, Ebers, G, Esiri, M

Axonal loss in the optic nerve and tract in multiple sclerosis by Esiri, M, Evangelou, N, Konz, D, Smith, S, Palace, J, Matthews, P

Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. by Gilmore, C, Bö, L, Owens, T, Lowe, J, Esiri, M, Evangelou, N

Extensive grey matter demyelination occurs in the spinal cord in multiple sclerosis by Gilmore, C, Bo, L, Owens, T, Lowe, J, Esiri, M, Evangelou, N

Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. by Evangelou, N, Konz, D, Esiri, M, Smith, S, Palace, J, Matthews, P

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab by Kitley, J, Evangelou, N, Küker, W, Jacob, A, Leite, M, Palace, J

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. by Kitley, J, Evangelou, N, Küker, W, Jacob, A, Leite, M, Palace, J

Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. by Gilmore, C, DeLuca, G, Bö, L, Owens, T, Lowe, J, Esiri, M, Evangelou, N

Spinal cord neuronal pathology in multiple sclerosis. by Gilmore, C, DeLuca, G, Bö, L, Owens, T, Lowe, J, Esiri, M, Evangelou, N

AMILORIDE CLINICAL TRIAL IN OPTIC NEURITIS: TRIAL PARADIGM by McKee, J, Elston, J, Evangelou, N, Fugger, L, Kennard, C, Palace, J, Craner, M

Decentralised clinical trials in multiple sclerosis research by Garjani, A, Liu, BJ-Y, Allen, CM, Gunzler, DD, Gerry, SW, Planchon, SM, das Nair, R, Chataway, J, Tallantyre, EC, Ontaneda, D, Evangelou, N